Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

ONC-841

ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.

Trial Locations (8)

32610

NOT_YET_RECRUITING

UF Health Cancer Center, University of Florida, Gainesville

34747

NOT_YET_RECRUITING

AdventHealth Medical Group Oncology Research at Celebration, Kissimmee

40202

RECRUITING

Norton Cancer Center, Louisville

48109

NOT_YET_RECRUITING

Rogel Cancer Center, University of Michigan, Ann Arbor

77598

RECRUITING

Tranquil Clinical Research, Houston

84112

NOT_YET_RECRUITING

Huntsman Cancer Institute, University of Utah, Salt Lake City

95817

RECRUITING

University of California at Davis Cancer Center, Sacramento

770360

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

OncoC4, Inc.

INDUSTRY